share_log

Recursion Pharmaceuticals | CORRESP: CORRESP

Recursion Pharmaceuticals | CORRESP: CORRESP

Recursion Pharmaceuticals | CORRESP：信函
美股SEC公告 ·  06/13 14:50

Moomoo AI 已提取核心信息

Recursion Pharmaceuticals, Inc. has responded to a series of comments from the SEC regarding their Form 10-K for the fiscal year ended December 31, 2023. The SEC's inquiries addressed several aspects of Recursion's financial reporting, including the terms and accounting treatments of collaboration agreements with Enamine and NVIDIA, as well as the upfront payment for the Tempus agreement. Recursion clarified that the Enamine agreement, which involves access to chemical compound libraries and is considered ordinary course with immaterial revenue, does not require additional disclosure. The company also confirmed that the $22.0 million upfront payment for the Tempus agreement was recorded as 'Research and Development' expense and detailed the accounting policy for such payments. Regarding the NVIDIA collaboration, Recursion stated that there are no material obligations or payment requirements, thus no additional disclosure was necessary. Additionally, Recursion will update future filings to correctly reflect that Net Loss, not Comprehensive Loss, is added to Accumulated Deficit and will confirm the effectiveness of internal controls over financial reporting.
Recursion Pharmaceuticals, Inc. has responded to a series of comments from the SEC regarding their Form 10-K for the fiscal year ended December 31, 2023. The SEC's inquiries addressed several aspects of Recursion's financial reporting, including the terms and accounting treatments of collaboration agreements with Enamine and NVIDIA, as well as the upfront payment for the Tempus agreement. Recursion clarified that the Enamine agreement, which involves access to chemical compound libraries and is considered ordinary course with immaterial revenue, does not require additional disclosure. The company also confirmed that the $22.0 million upfront payment for the Tempus agreement was recorded as 'Research and Development' expense and detailed the accounting policy for such payments. Regarding the NVIDIA collaboration, Recursion stated that there are no material obligations or payment requirements, thus no additional disclosure was necessary. Additionally, Recursion will update future filings to correctly reflect that Net Loss, not Comprehensive Loss, is added to Accumulated Deficit and will confirm the effectiveness of internal controls over financial reporting.
Recursion Pharmaceuticals, Inc.回应了美国证券交易委员会对其截至2023年12月31日财年的10-K表格的一系列评论。SEC的质询涉及到了Recursion的财务报告的几个方面，包括与Enamine和NVIDIA的合作协议的条款和会计处理方式，以及Tempus协议的预付款。Recursion澄清了Enamine协议，该协议涉及到化合物库的使用并被视为普通业务，营业收入微不足道，不需要额外的披露。该公司还确认了Tempus协议的2200万美元预付款已记录为“研究与开发”费用并详细说明了此类付款的会计政策。关于NVIDIA的合作，Recursion表示没有重大义务或付款要求，因此不需要额外的披露。此外，Recursion将更新未来的报告以正确反映净损失，而不是综合损失被累积赤字相加，并确认财务报告的内部控制的有效性。
Recursion Pharmaceuticals, Inc.回应了美国证券交易委员会对其截至2023年12月31日财年的10-K表格的一系列评论。SEC的质询涉及到了Recursion的财务报告的几个方面，包括与Enamine和NVIDIA的合作协议的条款和会计处理方式，以及Tempus协议的预付款。Recursion澄清了Enamine协议，该协议涉及到化合物库的使用并被视为普通业务，营业收入微不足道，不需要额外的披露。该公司还确认了Tempus协议的2200万美元预付款已记录为“研究与开发”费用并详细说明了此类付款的会计政策。关于NVIDIA的合作，Recursion表示没有重大义务或付款要求，因此不需要额外的披露。此外，Recursion将更新未来的报告以正确反映净损失，而不是综合损失被累积赤字相加，并确认财务报告的内部控制的有效性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间